NYXH Nyxoah

Conditional Issuance of Shares

Conditional Issuance of Shares

INSIDE INFORMATION

REGULATED INFORMATION

Conditional Issuance of Shares

Mont-Saint-Guibert, Belgium – April 16, 2025, 8:00 am CET / 2:00 am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), today announced a conditional issuance of up to 5 million ordinary shares under its existing at-the-market equity offering programs (the “ATM”). This brings the aggregate number of ordinary shares that can be sold and issued under the Company’s ATM to 5,662,694 (the “ATM Shares”), which includes 662,694 shares that are still available from the conditional issuance of shares under the ATM decided upon on December 22, 2022.

Pursuant to the existing sales agreement entered into by the Company on December 22, 2022, ATM Shares may be sold from time to time at a sales price per ATM Share equal to prevailing USD market prices of the Nyxoah ordinary share on the Nasdaq Global Market at the time of the sale.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy any securities.

Contacts:

Nyxoah

John Landry, CFO



Attachment



EN
16/04/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Nyxoah

 PRESS RELEASE

Conditional Issuance of Shares

Conditional Issuance of Shares INSIDE INFORMATIONREGULATED INFORMATION Conditional Issuance of Shares Mont-Saint-Guibert, Belgium – April 16, 2025, 8:00 am CET / 2:00 am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), today announced a conditional issuance of up to 5 million ordinary shares under its existing at-the-market equity offering programs (the “ATM”). This brings the aggregate number of ordinary shares that can be sold and issued under the Company’s ATM to 5,662,694 (the “ATM Shares”), which includes 662,694 shares that are still available from the ...

 PRESS RELEASE

Émission Conditionnelle d’Actions

Émission Conditionnelle d’Actions INFORMATIONS PRIVILÉGIÉESINFORMATIONS RÉGLEMENTÉES Émission Conditionnelle d’Actions Mont-Saint-Guibert, Belgique – le 16 avril 2025, 8:00h CET / 2:00h ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” ou la “Société”), a annoncé aujourd’hui une émission conditionnelle de jusqu’à 5 millions d’actions ordinaires dans le cadre de ses programmes d’offre d’actions “at the market” existants (l’“ATM”). Cela porte le nombre total d’actions ordinaires qui peuvent être vendues et émises dans le cadre de l’ATM de la Société à 5.662.694 (les “Actions ATM”)...

 PRESS RELEASE

Nyxoah Provides Update on FDA Approvable Letter for Genio System

Nyxoah Provides Update on FDA Approvable Letter for Genio System Nyxoah Provides Update on FDA Approvable Letter for Genio System Expects to meet final FDA requirements for full PMA approval in the second quarter Mont-Saint-Guibert, Belgium – April 8, 2025, 07:00am CET / 1:00am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), which develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced an update on the FDA approval process for the Genio system. On March 26, 2025, the Company announced that the U.S...

 PRESS RELEASE

Nyxoah Présente une Mise à Jour Concernant la Lettre d'Approuvabilité ...

Nyxoah Présente une Mise à Jour Concernant la Lettre d'Approuvabilité de la FDA pour le Système Genio Nyxoah Présente une Mise à Jour Concernant la Lettre d'Approuvabilité de la FDA pour le Système GenioPrévoit de satisfaire aux exigences finales de la FDA pour obtenir l'approbation PMA complète au cours du deuxième trimestre Mont-Saint-Guibert, Belgique – 8 avril 2025, 07h00 CET / 01h00 ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (« Nyxoah » ou la « Société »), une société de technologie médicale développant des alternatives thérapeutiques innovantes pour l'apnée obstructive du som...

Jamila El Bougrini ... (+2)
  • Jamila El Bougrini
  • Thibaut Voglimacci-Stephanopoli

ResearchPool Subscriptions

Get the most out of your insights

Get in touch